Literature DB >> 7505610

Phenotypic and functional heterogeneity of the IgD- B cell compartment: identification of two major tonsillar B cell subsets.

C Lagresle1, C Bella, T Defrance.   

Abstract

Two major B cell subpopulations were identified in the IgD- compartment of tonsils and subsequently isolated. They displayed the following phenotypes: CD10+CD38+CD44- (CD38+ B cells) and CD10-CD38-CD44+ (CD38- B cells). Of the CD38- B cells, 70% also expressed CD24 and CD39, whereas CD77 was specifically distributed on 40% of CD38+ B cells, suggesting an additional level of heterogeneity in the cellular composition of these two B cell types. Whereas the majority of CD38+ B cells were in cycle, most CD38- B cells were quiescent. Conversely, Bcl-2 was expressed in CD38- B cells but was not detected in CD38+ B cells. Of the CD38- B cells, 30% bore the homing receptor Leu-8/Mel-14, whereas CD38+ B cells lacked this marker. Thus, CD38- B cells have both survival capacity and migratory competence. Both subsets expressed surface (s) Igs which were mainly of the IgG class, implying that most of these cells have already undergone isotype switching. CD38- B cells proliferated vigorously and produced large amounts of IgG in response to cytokines, following ligation of slgs or CD40. In contrast, CD38+ B cells were only stimulated for DNA synthesis by a combination of IL-4 and anti-CD40 antibodies, and failed to differentiate into Ig-secreting cells regardless of the stimulus applied. We propose that CD38- B cells represent an extra-follicular mature B cell population which has been positively selected and rescued from apoptosis, whereas the CD38+ B cell subset is composed of germinal centre B cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505610     DOI: 10.1093/intimm/5.10.1259

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

1.  Memory B lymphocytes migrate to bone marrow in humans.

Authors:  E Paramithiotis; M D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

Review 2.  Differentiation and apoptosis of human germinal center B-lymphocytes.

Authors:  Y S Choi
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

3.  Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis.

Authors:  C Lagresle; P Mondière; C Bella; P H Krammer; T Defrance
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

4.  B lymphocyte-typing for prediction of clinical response to rituximab.

Authors:  Hans-Peter Brezinschek; Franz Rainer; Kerstin Brickmann; Winfried B Graninger
Journal:  Arthritis Res Ther       Date:  2012-07-06       Impact factor: 5.156

5.  B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement.

Authors:  C C Bleul; J L Schultze; T A Springer
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

6.  Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing.

Authors:  C Arpin; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

7.  Repression of BCL-6 is required for the formation of human memory B cells in vitro.

Authors:  Tracy C Kuo; Arthur L Shaffer; Joseph Haddad; Yong Sung Choi; Louis M Staudt; Kathryn Calame
Journal:  J Exp Med       Date:  2007-04-02       Impact factor: 14.307

8.  CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype.

Authors:  L Galibert; N Burdin; B de Saint-Vis; P Garrone; C Van Kooten; J Banchereau; F Rousset
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

9.  Negative selection of human germinal center B cells by prolonged BCR cross-linking.

Authors:  L Galibert; N Burdin; C Barthélémy; G Meffre; I Durand; E Garcia; P Garrone; F Rousset; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.